Kuvatris Therapeutics Inc (PXMD) Directors and Executive Officers

Officers & Directors

Zachary Rome
Director

Howard J. Weisman
Chairman of the Board and Chief Executive Officer (Principal Executive Officer)

Stephen Sheldon
Chief Financial Officer and Chief Operating Officer (Principal Financial Officer and Principal Accounting Officer)

Charles J. Casamento
Director

John F. Coelho
Director

Karen LaRochelle
Director ,

Kuvatris Therapeutics Inc currently has 10 employees.

News about Kuvatris Therapeutics Inc Key Personnel

PaxMedica Steps Up to Combat Sleeping Sickness Crisis in Malawi with Emergency Supply of IV Suramin

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica Inc. (Nasdaq: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, has announced its swift response to an urgent request from the Ministry of Health (MOH) of Malawi in east Africa. The MOH seeks emergency access to the company s newly registered PAX-101 (IV suramin) to address the critical shortage of medication required to combat the life-threatening sleeping sickness crisis in the region.
Sleeping sickness, also known as Trypanosoma brucei rhodesiense or Human African trypanosomiasis (TBr HAT), is a severe disease caused by the para...

PaxMedica Revolutionizes Autism Spectrum Disorder Treatments with Groundbreaking Innovations

PaxMedica Unveils Innovations in Autism Spectrum Disorder Treatments in Latest Company Presentation
TARRYTOWN, New York, March 13, 2024 - PaxMedica, Inc. (NASDAQ: PXMD), a leading biopharmaceutical company specializing in neurological disorder treatments, announced today the release of its latest company presentation. This comprehensive overview highlights PaxMedica s strategic direction, recent advancements in Autism Spectrum Disorder (ASD) therapeutics, and its unwavering commitment to addressing the unmet needs of the ASD community.
PaxMedica has long been at the forefront of developing innovative treatments for neurological disorders, with a particular focus on ASD. This latest company presentati...